Clifford Chance

Clifford Chance advises Keymed on transaction with Ouro Medicines, LLC/Platina Medicines Ltd

Global law firm Clifford Chance has advised Keymed Biosciences (HKSe: 02162) on its transaction with Ouro Medicines, LLC (OuroMed) / Platina Medicines Ltd (Platina).

As part of the transaction, Keymed has signed a licensing agreement granting Platina the exclusive worldwide rights to develop, manufacture and commercialize CM336 (a BCMAxCD3 bispecific antibody), excluding Greater China.

Platina is a subsidiary of OuroMed. OuroMed is founded by Monograph Capital in partnership with GSK plc, and has recently completed a US$120 million Series A financing. The investment was led by TPG Life Sciences Innovations, with co-investment from NEA and Norwest Venture Partners, and participation from UPMC, Boyu/Zoo Capital, LongRiver Investments, among others. The financing will be used to advance the development of CM336.

The deal was led by Shanghai partner Yang Yi and New York partner Matthew Warner. The partners were supported by a cross-border team of lawyers in Beijing, Hong Kong, New York and Washington, D.C. advising on M&A, intellectual property and international trade regulations aspects. Yi and Matthew are assisted by counsel Daryl Fairbairn in New York and counsel Ryan Wong in Hong Kong. Other team members include:

• Beijing: Associate Xiaohan Sun;
• Hong Kong: Associate Charmaine Lee;
• New York: Associate Vicki Ye;
• Shanghai: Trainee solicitor Ashley Tan; and
• Washington, D.C.: Partner Renee Latour and associate Holly Bauer.

In addition to this transaction, Clifford Chance has advised Keymed on two other out-licensing transactions which includes one with Timberlyne Therapeutics and one with Belenos Biosciences.